Form 4: Director Robert Schriesheim Plans HLI Stock Sale

Houlihan Lokey Director Robert Schriesheim filed a Form 4 indicating a future sale of 5,000 Class A Common Stock shares at $170.86 per share, likely under a 10b5-1 plan.

Summary

• Robert A. Schriesheim, a Director of Houlihan Lokey, Inc. (HLI), filed a Form 4 reporting a planned transaction.
• The filing indicates a disposition of 5,000 shares of Class A Common Stock.
• This transaction is scheduled for February 6, 2026, at a price of $170.86 per share.
• Following this planned sale, Mr. Schriesheim will beneficially own 27,982 shares directly.
• The transaction is explicitly stated to be made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an insider sale can sometimes be seen negatively, the 10b5-1 plan context and the director's retained significant holdings suggest a routine financial planning move rather than a lack of confidence in the company.

Positives

• The planned sale is under a Rule 10b5-1 plan, which suggests it is a pre-scheduled transaction for personal financial management and not based on new, non-public information.
• Mr. Schriesheim will retain a significant holding of 27,982 shares after the planned sale, indicating continued alignment with shareholder interests.

Negatives

• A director's planned sale of 5,000 shares, even under a 10b5-1 plan, could be perceived negatively by some investors as a reduction in insider ownership.
• The specific sale price of $170.86 per share represents a decision by the insider to sell at that valuation.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance, as it solely reports an insider's planned stock transaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are routinely monitored by investors for signals regarding management's confidence in the company's future prospects. While a director's sale of shares might sometimes raise questions, the explicit mention of a Rule 10b5-1 plan typically mitigates concerns that the sale is based on new, undisclosed negative information. Such plans are common for executives and directors to manage personal finances and diversify holdings over time.

Comparison to Industry Standards

• Insider sales under Rule 10b5-1 plans are a standard practice across publicly traded companies, including those in the financial services sector like Houlihan Lokey.
• Similar planned sales are observed at firms such as Lazard Ltd (LAZ) or Evercore Inc. (EVR), where executives periodically sell portions of their equity holdings for personal financial planning purposes.
• The volume of 5,000 shares represents a fraction of Mr. Schriesheim's total holdings, which is typical for such diversification efforts rather than a complete divestment.

Stakeholder Impact

• Shareholders: May interpret the planned sale as a routine diversification under a 10b5-1 plan, or potentially as a minor negative signal if they overlook the 10b5-1 context. The director retains substantial ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The planned transaction of 5,000 shares of Class A Common Stock is scheduled to occur on February 6, 2026.

Key Dates

Recommendation

This Form 4 filing reports a pre-planned insider sale under a Rule 10b5-1 plan, which is a routine event for corporate directors managing personal finances. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. The director retains a substantial stake, indicating continued alignment. Therefore, a "hold" recommendation is appropriate, as this specific filing does not present a compelling reason to alter an existing position based on company fundamentals.

Keywords

Houlihan Lokey, HLI, Form 4, Insider Trading, Stock Sale, Director, Robert Schriesheim, 10b5-1 plan, Equity Disposition